Download Full eBooks in PDF
Chemotherapy And The Immune System Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Chemotherapy And The Immune System book. This book definitely worth reading, it is an incredibly well-written.
Author : L. H. Chappell,M. J. Doenhoff
Publisher : Cambridge University Press
Page : 116 pages
File Size : 51,5 Mb
Release : 1992
Category : Medical
ISBN : 0521448352
This specially commissioned text covers a range of topics relating to chemotherapy and the immune system.
Author : Enrico Mihich
Publisher : Elsevier
Page : 414 pages
File Size : 43,7 Mb
Release : 2016-01-22
Category : Health & Fitness
ISBN : 9781483259000
Immunity, Cancer, and Chemotherapy focuses on the interference of drugs on antibody response and transplantation immunity. The selection first offers information on the effects of immunosuppressive drugs on cellular changes after antigenic stimulation and specialized cell function in the lymphoid and reticuloendothelial cell series. Topics include effects of immunosuppressive drugs on the sensitization process; cellular changes in lymphoid tissue following sensitization; and demonstration of differences in antigen handling among cells of the reticuloendothelial system. The text also takes a look at allogeneic inhibition and its possible relation to cell-bound immunity in vitro and the effects of immunosuppressive drugs at various stages of differentiation of immunologically competent cells. The publication examines a study of antibody-containing cells in the course of immunization and cellular differentiation during immune responses studied with electron microscope and radioautography. The text also elaborates on ambiguity in the translation of genetic code into proteins, induced by aminoglycoside antibiotics and immunosuppressive agents and cellular kinetics of immune response. The selection is a dependable source of information for readers interested in effects of drugs on antibody response and transplantation immunity.
Author : Gerhard Pulverer,J. Jeljaszewicz
Publisher : Unknown
Page : 264 pages
File Size : 50,9 Mb
Release : 1985
Category : Anti-infective agents
ISBN : UCAL:B4529124
Author : Robert Gorter, M.D., Ph.D.,Erik Peper, Ph.D.
Publisher : North Atlantic Books
Page : 385 pages
File Size : 54,6 Mb
Release : 2011-05-31
Category : Health & Fitness
ISBN : 9781583942833
Fighting Cancer describes the Gorter Model, an integrative, nontoxic approach to cancer treatment that mobilizes the immune system. It was developed by Robert Gorter, MD, PhD, who in 1976 recovered from Stage IV testicular cancer by using nontoxic treatment and no chemotherapy or radiation. Based on self-experience, extensive research, and decades of clinical practice, the treatment consists of supporting the immune system using fever therapy (hyperthermia), inoculation with immune cells, the use of the botanical mistletoe (Viscum album)—the single most commonly prescribed anti-cancer medication in much of Europe—supportive nutrients, and diet and lifestyle changes. Organized into three parts, Fighting Cancer presents a clear overview of the model, the research behind it, and strategies for strengthening natural immunity. Emphasizing stress reduction and minimizing toxic exposure, the authors provide practical guidance for patients: questions to ask doctors after diagnosis and advice for evaluating options, gathering information, and getting second opinions. Included are powerful testimonials from patients—most of whom have outlived their prognosis and, in some cases, achieved complete and sustained remission.
Author : W. Joost Lesterhuis,Anna K. Nowak,Richard A. Lake
Publisher : Elsevier Inc. Chapters
Page : 684 pages
File Size : 51,6 Mb
Release : 2013-06-04
Category : Medical
ISBN : 9780128059203
Studies over the past few years have caused a gestalt in thinking about chemotherapy and tumor immunity. Rather than regarding chemotherapy as an immunosuppressive inevitability, it is now recognized that chemotherapeutics can direct and amplify an immune response against cancer. In this chapter, we will review this field with emphasis on the mechanisms behind the immunopotentiating features of classic cytotoxic chemotherapeutics. We will discuss the most recent clinical translations in this field and review the current gaps in our knowledge. In addition we will outline the difficulties that lie ahead in optimally exploiting the immunopotentiating action of classical chemotherapeutics, and describe the way we think this field can move forward.
Author : Haidong Dong,Svetomir N. Markovic
Publisher : Springer
Page : 160 pages
File Size : 55,8 Mb
Release : 2018-01-05
Category : Medical
ISBN : 9783319706221
This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.
Author : Lisa H. Butterfield, PhD,Howard L. Kaufman, MD, FACS,Francesco M. Marincola, MD, FACS
Publisher : Springer Publishing Company
Page : 920 pages
File Size : 41,5 Mb
Release : 2017-06-28
Category : Medical
ISBN : 9781617052736
Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. Key Features: Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs Includes Online Access to the Digital Book
Author : Gabriele Multhoff,Alan G. Pockley,Udo S. Gaipl,Franz Rödel
Publisher : Frontiers E-books
Page : 131 pages
File Size : 50,7 Mb
Release : 2024-05-17
Category : Electronic
ISBN : 9782889191390
Numerous developments in molecular biology have led to an explosive growth in the knowledge underlying mechanisms of carcinogenesis, cell signalling, tumor progression and development of metastasis. However, cure of cancer is still hampered by the inherited capacity of tumors to become resistant to standard therapies, to metastasize from their initial location and to proliferate in other tissue compartments. Radiotherapy is one of the main treatment modalities to achieve locoregional tumor control. However, the treatment of distant metastases further remains to be a challenge. In this special topic we are interested to elucidate immunological aspects which are initiated and affected by radiotherapy. We also aim to describe the development of innovative immunological strategies from a preclinical stage to clinical application which could be combined with standard radiotherapeutic approaches. A special interest will also deal with the effects of radiotherapy on tumor initiating cells as well as on the tumor microenvironment. Last but not least the effects of different irradiation sources and qualities such as photones, protones and heavy ions will be analyzed with respect to immunological outcome.
Author : Abhishek D Garg,Patrizia Agostinis
Publisher : Frontiers Media SA
Page : 147 pages
File Size : 50,8 Mb
Release : 2016-04-29
Category : Electronic book
ISBN : 9782889198382
Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.
Author : Laurence Zitvogel,Guido Kroemer
Publisher : Springer
Page : 724 pages
File Size : 54,5 Mb
Release : 2017-12-13
Category : Medical
ISBN : 9783319624310
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
Author : T. H. M. Stewart,E. Frederick Wheelock
Publisher : CRC Press
Page : 559 pages
File Size : 49,7 Mb
Release : 2017-07-28
Category : Medical
ISBN : 9781351367721
Cellular Immune Mechanisms and Tumor Dormancy features the work of internationally recognized experts from various disciplines as they discuss the phenomenon of tumor dormancy in humans. Animal models are described in which cellular and molecular components of the immune control of dormancy have been identified, and the relevance of these models to human cancer patients is recognized. Data derived from studies of organ transplantation, adjuvant chemotherapy, radiotherapy, anaesthesia, surgery, and whole blood transfusion is presented to show the vulnerability of cellular mechanisms maintaining dormancy. The potential for increasing the incidence of dormancy in micro metastases is also shown for non-small cell lung cancer, lymphoma, and leukemia. Cellular Immune Mechanisms and Tumor Dormancy is an important reference volume that will benefit researchers from many disciplines, including immunologists, pathologists, surgeons, and clinicians
Author : Mahbuba Rahman
Publisher : Bentham Science Publishers
Page : 167 pages
File Size : 41,6 Mb
Release : 2016-06-07
Category : Medical
ISBN : 9781681083070
Over the past decades, systems biology approaches have been applied in different areas of life science research including oncology. Researchers now understand the hallmarks of cancer cells such as abnormal cell growth, inflammation, dysregulated metabolic pathways and drug resistance properties at a molecular level. Systems biology approaches have enabled researchers to investigate cancer immunology by identifying cancer related biomarkers on immune cells, and to study the effect of different therapies in tissue cultures and mouse models. Systems Biology in Cancer Immunotherapy explains the scope of systems biology in understanding the immune response to neoplasms. The book introduces readers to the concepts crucial to cancer immunology before delving into the applied systems biology topics such as the metabolic pathways in cancer cells, the biomolecular roles of signal transduction molecules and their respective biochemical pathways ad cancer immunotherapy. A brief conclusion at the end also provides some information from a clinical and commercial perspective on cancer immunotherapy. This volume is intended as an introductory reference for life science and medical students, researchers and academics interested in the application of systems biology to the immune system in oncology research and chemotherapy practice.
Author : Alan P. Lyss,Humberto Fagundes,Patricia Corrigan
Publisher : John Wiley & Sons
Page : 384 pages
File Size : 55,7 Mb
Release : 2011-05-18
Category : Health & Fitness
ISBN : 9781118069998
An informative, compassionate guide for cancer patients and their loved ones Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and resources can help in the recovery process.
Author : Paul D. Rennert
Publisher : Springer
Page : 276 pages
File Size : 40,6 Mb
Release : 2016-05-30
Category : Medical
ISBN : 9783319298276
Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
Publisher : National Academies Press
Page : 89 pages
File Size : 45,9 Mb
Release : 2019-10-05
Category : Medical
ISBN : 9780309490863
In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16â€"17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.